Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Public ClinicalTrials.gov record NCT00510510. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo Controlled, Parallel Group, Multi-center Study, to Assess the Safety and Tolerability of 28 Days Treatment With NVA237 (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study assessed the safety/tolerability of 28 days of treatment with NVA237 100 µg and 200 µg once a day, compared to placebo in patients with moderate or severe Chronic Obstructive Pulmonary Disease (COPD).
Study identification
- NCT ID
- NCT00510510
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 281 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2007
- Primary completion
- Dec 31, 2007
- Completion
- Dec 31, 2007
- Last update posted
- May 20, 2012
2007 – 2008
United States locations
- U.S. sites
- 16
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis investigative site | Glendale | Arizona | 85306 | — |
| Novartis investigative site | Phoenix | Arizona | 85006 | — |
| Novartis investigative site | Wheat Ridge | Colorado | 80033 | — |
| Novartis investigative site | Newark | Delaware | 19713 | — |
| Novartis investigative site | Miami | Florida | 33143 | — |
| Novartis investigative site | Miami | Florida | 33169 | — |
| Novartis investigative site | Tamarac | Florida | 33321 | — |
| Novartis investigative site | River Forest | Illinois | 60305 | — |
| Novartis investigative site | Overland Park | Kansas | 66210-2761 | — |
| Novartis investigative site | Saint Chares | Missouri | 63301 | — |
| Novartis investigative site | Charlotte | North Carolina | 28207 | — |
| Novartis investigative site | Portland | Oregon | 97213 | — |
| Novartis investigative site | Spartanburg | South Carolina | 29303 | — |
| Novartis investigative site | Union | South Carolina | 29379 | — |
| Novartis investigative site | Fort Worth | Texas | 76104 | — |
| Novartis investigative site | Houston | Texas | 77024 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00510510, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 20, 2012 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00510510 live on ClinicalTrials.gov.